A seven-gene prognostic signature predicts overall survival of patients with lung adenocarcinoma (LUAD)

Cancer Cell International

Yu Zhang¹  Jingkai Zhang¹  Yulong Li¹  Sufiyan Sufiyan¹  Yichen Wang¹  Rulin Hua¹  Dekang Lv¹  Ruimei Liu¹  Zhiguang Li¹  Yanyan Shao¹  Qi-Tian Huang¹  Quentin Liu¹  Wanting Bai¹  Dongcen Ge¹  Xuehong Zhang¹  Chao Huang¹  Aisha Al-Dherasi²  Haithm Mousa³  Sultan Al-Mosaib⁴  Leming Shi⁵  Ying Yu⁵  Yuwei Liao⁶ 

[1] Center of Genome and Personalized Medicine, Institute of Cancer Stem Cell, Dalian Medical University, 116044, Dalian, Liaoning, People’s Republic of China;Center of Genome and Personalized Medicine, Institute of Cancer Stem Cell, Dalian Medical University, 116044, Dalian, Liaoning, People’s Republic of China;Department of Biochemistry, Faculty of Science, Ibb University, Ibb, Yemen;Department of Clinical Biochemistry, College of Laboratory Diagnostic Medicine, Dalian Medical University, 116044, Dalian, Liaoning, People’s Republic of China;Department of Computer Science and Technology, Sahyadri Science College, Kuvempu University, Shimoga, Karnataka, India;State Key Laboratory of Genetic Engineering, School of Life Sciences and Human Phenome Institute, Fudan University, 2005 Songhu Road, 200438, Shanghai, People’s Republic of China;Yangjiang Key Laboratory of Respiratory Diseases, Yangjiang People’s Hospital, Yangjiang, Guangdong Province, People’s Republic of China;

关键词: Lung adenocarcinoma (LUAD);    Overall survival;    Risk score;    Prognostic signature;   

DOI  :  10.1186/s12935-021-01975-z

来源: Springer

【 摘 要 】

BackgroundLung adenocarcinoma (LUAD) is one of the most common types in the world with a high mortality rate. Despite advances in treatment strategies, the overall survival (OS) remains short. Our study aims to establish a reliable prognostic signature closely related to the survival of LUAD patients that can better predict prognosis and possibly help with individual monitoring of LUAD patients.MethodsRaw RNA-sequencing data were obtained from Fudan University and used as a training group. Differentially expressed genes (DEGs) for the training group were screened. The univariate, least absolute shrinkage and selection operator (LASSO), and multivariate cox regression analysis were conducted to identify the candidate prognostic genes and construct the risk score model. Kaplan–Meier analysis, time-dependent receiver operating characteristic (ROC) curve were used to evaluate the prognostic power and performance of the signature. Moreover, The Cancer Genome Atlas (TCGA-LUAD) dataset was further used to validate the predictive ability of prognostic signature.ResultsA prognostic signature consisting of seven prognostic-related genes was constructed using the training group. The 7-gene prognostic signature significantly grouped patients in high and low-risk groups in terms of overall survival in the training cohort [hazard ratio, HR = 8.94, 95% confidence interval (95% CI)] [2.041–39.2]; P = 0.0004), and in the validation cohort (HR = 2.41, 95% CI [1.779–3.276]; P < 0.0001). Cox regression analysis (univariate and multivariate) demonstrated that the seven-gene signature is an independent prognostic biomarker for predicting the survival of LUAD patients. ROC curves revealed that the 7-gene prognostic signature achieved a good performance in training and validation groups (AUC = 0.91, AUC = 0.7 respectively) in predicting OS for LUAD patients. Furthermore, the stratified analysis of the signature showed another classification to predict the prognosis.ConclusionOur study suggested a new and reliable prognostic signature that has a significant implication in predicting overall survival for LUAD patients and may help with early diagnosis and making effective clinical decisions regarding potential individual treatment.

【 授权许可】

CC BY